Early research (Phase 1)UnknownNCT04318964What this trial is testingTAEST16001 in the Treatment of Soft Tissue SarcomaWho this might be right forSoft Tissue Sarcoma Sun Yat-sen University 12
Early research (Phase 1)Looking for participantsNCT06942143What this trial is testingAn Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1-positive Patients With Advanced Solid TumorsWho this might be right forSarcomaLung CancersMelanoma Guangzhou FineImmune Biotechnology Co., LTD. 15
Testing effectiveness (Phase 2)Ended earlyNCT03709706What this trial is testingPilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With PembrolizumabWho this might be right forNeoplasms GlaxoSmithKline 34
Early research (Phase 1)Ended earlyNCT03168438What this trial is testingLetetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple MyelomaWho this might be right forNeoplasms GlaxoSmithKline 6
Early research (Phase 1)Active Not RecruitingNCT02869217What this trial is testingStudy of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid TumorsWho this might be right forNY-ESO-1 Expressing Solid Tumors in HLA-A2 Positive PatientsSynovial SarcomaMelanoma+5 more University Health Network, Toronto 22
Early research (Phase 1)Looking for participantsNCT05989828What this trial is testingA2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast CancerWho this might be right forTriple Negative Breast Cancer University of Southern California 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT03967223What this trial is testingMaster Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid TumorsWho this might be right forNeoplasms USWM CT, LLC 103
Early research (Phase 1)Ended earlyNCT03240861What this trial is testingGenetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced CancerWho this might be right forHLA-A*0201 Positive Cells PresentLocally Advanced Malignant NeoplasmNY-ESO-1 Positive+2 more Jonsson Comprehensive Cancer Center 5
Early research (Phase 1)Study completedNCT03450122What this trial is testingModified T Cells, Chemotherapy, and Aldesleukin With or Without LV305 and CMB305 in Treating Participants With Advanced or Recurrent SarcomaWho this might be right forHLA-A*0201 Positive Cells PresentNY-ESO-1 Positive Tumor Cells PresentRecurrent Myxoid Liposarcoma+1 more M.D. Anderson Cancer Center 15
Very early researchUnknownNCT05648994What this trial is testingTCR-T Cells for the Treatment NY-ESO-1-positive Advanced Solid TumorsWho this might be right forSolid Tumors Fujian Cancer Hospital 30
Early research (Phase 1)Looking for participantsNCT05881525What this trial is testingNY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid TumorsWho this might be right forAdvanced Solid Tumors TCRCure Biopharma Ltd. 18
Early research (Phase 1)WithdrawnNCT03506802What this trial is testingTCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple MyelomaWho this might be right forHLA-A*0201 Positive Cells PresentNY-ESO-1 Positive Tumor Cells PresentRecurrent Plasma Cell Myeloma+1 more Jonsson Comprehensive Cancer Center
Testing effectiveness (Phase 2)Study completedNCT05993299What this trial is testingStudy to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell LiposarcomaWho this might be right forNeoplasms USWM, LLC (dba US WorldMeds) 7
Testing effectiveness (Phase 2)Ended earlyNCT05549921What this trial is testingPhase II Study of TAEST16001 in Soft Tissue SarcomaWho this might be right forSoft Tissue Sarcoma Sun Yat-sen University 8
Early research (Phase 1)Study completedNCT01522820What this trial is testingVaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid TumorsWho this might be right forAnaplastic AstrocytomaAnaplastic OligoastrocytomaAnaplastic Oligodendroglioma+62 more Roswell Park Cancer Institute 18
Testing effectiveness (Phase 2)Ended earlyNCT03515551What this trial is testingSafety and Efficacy of IMCnyeso in Advanced NY-ESO-1 and/or LAGE-1A Positive CancersWho this might be right forSelect Advanced Solid Tumors Immunocore Ltd 29
Large-scale testing (Phase 3)Looking for participantsNCT07174427What this trial is testingMulti-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial SarcomaWho this might be right forSynovial Sarcomas Takara Bio Inc. 5
Early research (Phase 1)Study completedNCT02588612What this trial is testingLetetresgene Autoleucel Engineered T Cells in NY-ESO -1 Positive Advanced Non-Small Cell Lung Cancer (NSCLC)Who this might be right forNeoplasms GlaxoSmithKline 10
Early research (Phase 1)Ended earlyNCT05943990What this trial is testingStudy of GSK3845097 in Previously Treated Participants With Advanced Synovial Sarcoma and Myxoid/Round Cell LiposarcomaWho this might be right forNeoplasms Adaptimmune 5
Testing effectiveness (Phase 2)Study completedNCT02992743What this trial is testingLetetresgene Autoleucel Engineered T Cells in NY-ESO-1 Positive Participants With Advanced Myxoid/ Round Cell LiposarcomaWho this might be right forNeoplasms GlaxoSmithKline 23